Clearstead Advisors’s Moleculin Biotech MBRX Stock Holding History

Clearstead Advisors’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2	Closed	-$636	–	1402
2022 Q4	$636	Buy	+2	New	+$844	﹤0.01%	1209

Other funds holding MBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Clearstead Advisors's MBRX Position: Q1 2023 in Review

Clearstead Advisors sold out of Moleculin Biotech (MBRX) in Q1 2023, closing a stake of 2 shares — an estimated $636 sold.

Clearstead Advisors first reported a position in MBRX in Q4 2022 and held it in 1 quarter. The position peaked at $636 in Q4 2022. 22 funds tracked by Wall St. Rank hold MBRX as of Q1 2023.

Clearstead Advisors reported no remaining Moleculin Biotech position as of Q1 2023 after selling out during the quarter.
Clearstead Advisors sold 2 Moleculin Biotech shares in Q1 2023, an estimated $636.
Clearstead Advisors first reported a position in Moleculin Biotech in Q4 2022 and held it in 1 quarter.
Clearstead Advisors's Moleculin Biotech position peaked at $636 in Q4 2022.
22 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2023.

Based on Clearstead Advisors's 13F filing for Q1 2023, filed 9 May 2023.